Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

8 results about "Dienedione" patented technology

Dienedione, also known as estra-4,9-diene-3,17-dione, is a synthetic, orally active anabolic-androgenic steroid (AAS) of the 19-nortestosterone group that was never introduced for medical use. It is thought to be a prohormone of dienolone. The drug became a controlled substance in the US on January 4, 2010, and is classified as a Schedule III anabolic steroid under the United States Controlled Substances Act. Previous to this, it was sold as a bodybuilding supplement within the United States, and often mistakenly marketed as a prohormone for trenbolone, a veterinary steroid. Prior to its scheduling, it was part of a number of supplements that were seized during FDA enforcement of Bodybuilding.com for selling unapproved new drugs. The actual active metabolite, dienolone, is almost identical to trenbolone structurally, but lacks the C11 double bond.

Construction and application of c14 alpha hydroxylase cyp14 mutants

The application discloses a steroid C14 alpha hydroxylase CLCYP14 mutant, relates to the field of proteins, and applies a site-directed saturation mutation technology and a combination mutation strategy to screen and obtain CLCYP14 mutants I111L-M115K and I111L-V124W with high hydroxylation specificity. Compared with CLCYP14, the hydroxylation selectivity and conversion rate of I111L-M115K and I111L-V124W for steroid compounds progesterone, 21-hydroxyprogesterone, 5beta-hydroxyprogesterone, 1-dehydroprogesterone, 21-hydroxypregna-1,4-diene-3,20-dione and deoxycortisone are obviously improved.
Owner:SHANGHAI JIAOTONG UNIV

A curcumin analogue, preparation method and application thereof

This invention provides a curcumin analogue, its preparation method, and its application, belonging to the field of biomedical technology. The curcumin analogue includes 1,7-bis(3-hydroxy-4-methoxyphenyl)-4-n-butyl-1,6-heptadien-3,5-dione, 1,7-bis(3-hydroxy-4-methoxyphenyl)-4-cyclopropylmethyl-1,6-heptadien-3,5-dione, and 1,7-bis(3-trifluoromethoxyphenyl)-4-n-butyl-1,6-heptadien-3,5-dione. The curcumin analogue provided by this invention can effectively inhibit renal fibrosis, with a significantly better therapeutic effect than curcumin alone, and has potential application value in the field of renal fibrosis treatment drugs.
Owner:THE FIRST HOSPITAL OF LANZHOU UNIV

Preparation method of didrogesterone

PendingCN121426856ASteroidsSexual disorderDouble bondPregnanetriolone
The invention relates to the field of preparation of steroid drugs, and discloses a preparation method of didrogesterone. The preparation method disclosed by the invention comprises the following steps: by taking 9beta, 10alpha-pregna-4, 7-diene-3, 20-diketone as a starting material, carrying out intramolecular 7, 8-double bond transposition in the presence of organic silicon Lewis acid, so as to obtain the didrogesterone. The preparation method of the didrogesterone, provided by the embodiment of the invention, has the beneficial effects that (1) the purity of a refined product can reach 99% or above, the impurity content is controllable, and the total yield can be increased to 85% or above; reaction conditions are mild, operation is simple, and the method is suitable for industrial production.
Owner:ZHEJIANG XIANJU PHARMA

A 3-ketosteroid delta1-dehydrogenase mutant and use thereof in catalyzing dehydrogenation of steroid compounds

The application discloses a 3-steroid ketone-delta 1-dehydrogenase mutant and application thereof in catalyzing dehydrogenation of a steroid compound, and the mutant with high catalytic activity is screened, and a cosolvent Tween-80 is added to increase solubility of a substrate and then improve biological catalytic efficiency.Under optimal conditions, the mutant can increase the conversion rate of (16alpha)-methyl androst-4,9-diene-3,17-dione 15g / L to 99.9%.
Owner:ZHEJIANG UNIV OF TECH

Method for degrading 2-((4-methylpent-2-yl) amino)-5-(phenyl amino) cyclohex-2, 5-diene-1, 4-diketone by combining laccase and mediator

The invention discloses a method for jointly degrading 2-((4-methylpent-2-yl) amino)-5-(phenyl amino) cyclohex-2, 5-diene-1, 4-diketone by laccase and a mediator, and belongs to the technical field of environmental organic pollutant treatment.The specific method comprises the steps that mother liquor of pollutants is added into a conical flask, and after acetonitrile volatilizes, the mother liquor of the pollutants is added into the conical flask; the method comprises the following steps: adding a laccase ABTS mediator solution formed by mixing ABTS and laccase to form a reaction system with the pH value of 6.0, reacting at the constant temperature of 40 DEG C for 120 hours, extracting the pollutant by utilizing dichloromethane to terminate the reaction, and determining the residual concentration of the pollutant in the reaction system by adopting an ultra-high performance liquid chromatography so as to analyze the degradation effect of the pollutant. According to the method, a laccase ABTS mediator reaction system is constructed and used for degrading the pollutant 2-((4-methylpent-2-yl) amino)-5-(phenyl amino) cyclohex-2, 5-diene-1, 4-diketone, so that the degradation rate of the pollutant with the initial concentration of 1.0 mg / L reaches 80% or above, and an efficient method is provided for degrading the pollutant in the environment.
Owner:GUILIN UNIVERSITY OF TECHNOLOGY

Mycobacterium gene engineering bacteria with high yield of add and application thereof

The present application relates to an aldehyde mutarotase gene salA and its application in constructing a high-ADD-producing genetically engineered mycobacterium, and a high-ADD-producing genetically engineered mycobacterium and its construction and application in preparing 1,4-androstadiene-3,17-dione by microbial fermentation. The high-ADD-producing genetically engineered mycobacterium is obtained by knocking out kshA1, MnOpccR and salA genes in turn using mycobacterium as a chassis. The genetically engineered strain provided by the present application effectively controls the generation of by-products, greatly improves the utilization rate of steroidal substrates and the molar conversion rate of products, simplifies the post-processing process, and the strategy can also be applied to the synthesis of products in the common synthesis path of 1,4-androstadiene-3,17-dione and 9-OH-AD, which is microbial transformation of side chain degradation using phytosterol as a substrate, completely blocks the synthesis of 4-HBC and 1,4-HBC by-products, and reduces the burden of downstream separation while improving the utilization rate of phytosterol substrate. The present application has certain universality, is suitable for vigorous popularization and application, and has high economic and social benefits.
Owner:ZHEJIANG UNIV OF TECH

Dehydrogenase, gene, engineered bacteria and application

ActiveCN116240183BHigh dehydrogenation activityEfficient secretionBacteriaMicroorganism based processesEnzyme GeneEngineered genetic
The application belongs to the technical field of biocatalytic synthesis of steroid drugs, and particularly relates to a dehydrogenase, a gene, an engineering bacterium and application, the amino acid sequence of the dehydrogenase is SEQ ID NO. 1 or SEQ ID NO. 2, the dehydrogenase has high dehydrogenation activity, high stereoselectivity and strong regioselectivity, and no other conformation impurities are generated; the engineering bacterium can efficiently secrete the dehydrogenase, and effectively improves the conversion efficiency of a substrate, especially for a substrate 6-methy format (11beta, 17alpha-dihydroxy-6alpha-methylpregna-1, 4-diene-3, 20-diketone), which is low in cost and has significant industrialization potential; the dehydrogenase mutant has clear physicochemical properties, and the method of whole cell catalysis is used, so that the cumbersome step of enzyme purification is omitted, and the cost is reduced and the operation is simple.
Owner:HUNAN NORCHEM PHARMACEUTICAL CO LTD